Lasofoxifene as a potential treatment for ER+ metastatic breast cancer.

1056Background: Estrogen receptor positive (ER+) metastatic breast cancers (MBC) that express constitutively active somatic ESR1 mutations at Y537S and D538G allow tumors to progress in the presenc...